Inhaled nitric oxide (iNO) can reduce pulmonary arterial hypertension and improve oxygenation in some patients with severe respiratory or heart failure. Despite this, iNO has not been found to improve survival.
In the critically ill, inhaled nitric oxide (iNO) is used to relax smooth muscle of the pulmonary circulation in patients with pulmonary hypertension associated with right heart failure and to improved ventilation-perfusion matching in severe respiratory failure 1, 2 . Toxicity principally relates to the formation of methaemoglobin, nitrogen dioxide and increased bleeding time 3 . However, iNO appears safe and free from significant side-effects when used at concentrations less than 40 ppm 1 . Inhaled nitric oxide is expensive 4 and licensed in Australia and New Zealand only for use in pre-term neonates. Despite its ability to improve physiological parameters, there is currently little evidence to suggest it affects morbidity or mortality 1, [5] [6] [7] [8] . This study aimed to analyse the clinical usage patterns and adverse outcomes in patients prescribed iNO in a tertiary referral intensive care unit (ICU) where the use of iNO had been established since 1996.
MATERIALS AND METHODS
A retrospective audit of all patients receiving iNO in the ICU of the Royal Brisbane and Women's Hospital was conducted between 1 January 2004 and 31 December 2009. The data had been prospectively collected within a computerised clinical information system (Careview and IntelliVue Clinical Information Portfolio. Phillips, Einhoven. The Netherlands) and the hospital pathology database, AUSLAB.
Data collection included patient demographics, Acute Physiology and Chronic Health Evaluation (APACHE) II 9 , Simplified Acute Physiology Score (SAPS) II 10 and Charlson comorbidity scores 11 . Patient outcomes, additional respiratory therapies (other than iNO), acute respiratory distress syndrome (ARDS) 12, 13 and acute lung injury 13 were also recorded. Sequential Organ Failure Assessment (SOFA) scores 14 were collected on admission, prior to iNO and 24 hours after iNO commencement. 'Responders' to iNO were patients where an increase of the P a O 2 /FiO 2 ratio of 15% or greater from baseline or a decrease of pulmonary vascular resistance (PVR) 15% or greater from baseline after one hour of iNO treatment 1, [5] [6] [7] [8] . Methaemoglobin concentrations were performed using co-oximetry arterial blood gas analysis with results available from the database of the IntelliVue system for only 170 patients. The frequency of arterial blood gas analysis was clinically determined by the treating clinician.
Institutional Human Research Ethics Committee waivered the need for individual patient consent based on the retrospective nature of the study and de-identification of individual patient records.
STATISTICAL ANALYSIS
Using an a of 0.05 and a power of 0.8, with estimated mortality of patients receiving iNO in general of 0.5, an absolute risk reduction of 0.2 for mortality required 103 patients per group ('responders' compared to 'non-responders') using a Fisher's exact test for two proportions 15 . The fiveyear period under study accommodated the number of patients available for the review. Continuous data was analysed using Student's t-tests and Kruskal-Wallis tests and categorical data was analysed using Pearson's chi-squared and Fisher's exact test as appropriate. Forward stepwise multiple logistic regression modelling was used to find associations between clinical parameters and mortality outcome, and to adjust for the potential confounding effects of socio-demographic variables, comorbidities and presence and site of infection in each group. Regression models were assessed for goodness of fit using the method of Hosmer and Lemeshow 16 . Linear regression was used to assess the relationships between iNO therapy, organ failures and methaemoglobin concentrations in arterial blood. All tests of significance were twotailed and probability values less than 0.05 were considered significant 17, 18 . analysis of variance was used to assess the usage of iNO during the study period while a repeated measures analysis of variance was used to assess the serial SOFA scores. Results were reported as means and medians as appropriate. Where descriptive data related to measures of central tendency, 95% confidence intervals (CI) were estimated using binomial exact methods for medians. Data were analysed using STATA 9 (College Station, Texas, USA) statistical software. 
RESULTS
From January 2004 to December 2009, 215 patients received iNO, with a mean age of 52 years (95% CI 50 to 55), APACHE II score of 27 (95% CI 26 to 28) and SAPS II score of 54 (95% CI 51 to 56). The median ICU and hospital lengths of stay were 10.2 days (95% CI 8.9 to 12.5) and 26.8 days (95% CI 22 to 29) respectively. Patient characteristics are summarised in Table 1 . Patients had a median Charlson comorbidity score of 1 (95% CI 1 to 2) most commonly chronic pulmonary disease (20%) and myocardial infarction (16%) ( Table 1 ). The ICU services a large state-based bone marrow transplantation unit. Nearly 50% of patients with lymphoma and leukaemia as comorbidities were patients who had received bone marrow transplants. ARDS was diagnosed in 162 patients (75%) and acute lung injury in 11 patients (5%). The most common indication for initiating iNO therapy was hypoxaemia (91%), with several patients having multiple indications for iNO ( Table 2 ). There was no significant change in the duration of iNO use per patient over the study period (P=0.29).
The median peak iNO concentration used was 20 ppm (95% CI 19.8 to 22.2). Twenty-three patients received iNO at concentrations greater than 20 ppm (range 21 to 43). Of these, 12 patients were receiving therapy for pulmonary hypertension (seven with concurrent severe hypoxaemia) with the remainder having respiratory failure alone. The median positive end expiratory pressure at the commencement of iNO was 12 cmH 2 O (95% CI 12 to 12.5). There were 117 iNO 'responders' (54%). The median duration of iNO therapy in all patients was 1.9 days (95% CI 1.6 to 2.4) which was similar in 'responders' and 'non-responders' (P=0.57). There was no difference between the median individual nonrespiratory organ SOFA scores 24 hours following commencement of iNO in 'responders' compared to 'non-responders' (P=0.38 to 0.85). For all patients, the median SOFA scores increased in the time from admission to an hour before iNO was commenced (7 compared to 10, P <0.001), but did not change in the 24 hours following commencement of iNO (10 compared to 9, P=0.24).
Following iNO therapy, three patients (1.4%) developed documented pulmonary haemorrhage and 79 patients (37%) were reported to be coagulopathic in their chart notes. Renal replacement therapy was given to 99 patients (46%) during the study period with 52 patients (24%) starting renal replacement therapy after iNO was commenced (P=0.64).
The median duration of iNO therapy was 1.9 days (95% CI 1.6 to 5.4) and the median dose-time was 101 ppm-hours (95% CI 88 to 114). There was no difference in the duration of iNO wean between 'responders' and 'non-responders' (P=0.14). Once weaning from iNO commenced, the median time until iNO was ceased was 4.5 hours (95% CI 3 to 6.5). Two patients required weaning times of greater than 100 hours (164 and 233 hours respectively). Of the patients able to be weaned from iNO, 24% required several attempts to finally wean the iNO. Of these patients, the median number of weaning attempts was two (95% CI 2 to 2) with two patients requiring three and another two patients requiring four weaning attempts.
In the 170 patients where methaemoglobin concentrations were available, the median peak methaemoglobin concentration was 1.5% with no difference noted between 'responders' and 'nonresponders' (P=0.91). A peak methaemoglobin concentration was greater than 3% in five patients. Monitoring protocols were designed to keep the methaemoglobin concentration less than 3%. The median time to the peak of the methaemoglobin concentration was 11.0 hours following the commencement of iNO (95% CI 9.1 to 18). A high methaemoglobin concentration was associated with the SOFA score on day 1 of iNO administration (β=0.04, P=0.04) but not the change in the SOFA scores during the first 24 hours (P=0.36). There was no relationship between the iNO-time and the peak methaemoglobin concentration (P=0.69). The ICU mortality rates were similar in patients where methaemoglobin were and were not available (44% compared to 49%, P=0.52) There were 96 patients who died in ICU (45%), the most common causes being intractable respiratory failure (28%) and cardiovascular failure (28%) ( Table 1 ). Response to iNO did not predict ICU mortality (40% 'responders' and 50% 'nonresponders'. P=0. 17) . Table 4 details the univariate associations with ICU mortality. The independent risk factors for ICU mortality were the change in SOFA scores within 24 hours of commencing iNO (AOR 1.07, 95% CI 1.05 to 1.18), Charlson Comorbidity Score (AOR 1.49, 95% CI 1.16 to 0.1.91) and peak methaemoglobin concentration in arterial blood while receiving iNO (AOR 2.67, 95% 1.42 to 4.96) ( Table 4 ).
DISCUSSION
The main findings of our study confirmed that the administration of iNO conferred no survival benefit in 'responders' over 'non-responders'. In addition, we demonstrated the novel finding of peak methaemoglobin predictor of mortality despite its concentration generally being less than 3% and within the recommended safety range.
Inhaled nitric oxide has been found to acutely improve oxygenation in patients with ARDS, typically during the first 48 hours of therapy, and most effectively in doses between 5 to 10 ppm 2, 19 . In one study of 40 patients, iNO significantly reduced the incidence of extracorporeal membrane 20 . Research in the area of ARDS treatment is complicated by the heterogeneity of this condition, uncertainty about appropriate outcome measures, the variability in treatment between physicians and the difficulty in designing adequately blinded studies, as the effects of iNO are often readily apparent 1, 6, 21 . Also, most patients dying from ARDS perish as a result of multiple organ system failure, rather than hypoxaemia 1, 21 .
However, iNO has failed to demonstrate a mortality benefit when studied in randomised controlled trials 5 . We concur with these findings.
Most of the patients in our cohort had received iNO for ARDS or acute lung injury. However, there were patients included with pulmonary hypertension and small number of patients received doses higher than 20 ppm. In addition, five patients did have pulmonary haemorrhage as the cause of severe respiratory failure as the indication for iNO. This remains a controversial area given the potential antiplatelet effects of iNO. Two pulmonary haemorrhage patients died from progressive respiratory failure and one from multiorgan failure.
Despite the controversy surrounding iNO, most authors consider it reasonable to use as a rescue therapy for severe hypoxaemia refractory to conventional treatment 5, 6, 8, 19, 22 . Some authors argue that iNO use is associated with higher costs, which provides a financial rationale for limiting treatment for patients without expected survival benefit 4 . Nevertheless, no significant difference in hospital costs exists between iNO and placebo treated groups after one year 23 . However, this and other trials have been industry sponsored 17, 23 . Current trials have not specifically studied iNO as a rescue therapy for patients with critically low oxygenation, perhaps because of the challenges in enrolling such severely ill patients 5 .
To the best of our knowledge, this is the first study to find an association between methaemoglobinaemia and mortality in a cohort of critically ill patients receiving iNO therapy. We found that peak methaemoglobin concentrations in arterial blood predicted mortality. Methaemoglobin contains ferric iron, which prevents oxygen carriage and gives the unaltered haemoglobin a higher affinity for oxygen, resulting in the oxygen dissociation curve being shifted to the left [24] [25] [26] . Oxidation of haemoglobin to the methylated form occurs naturally in the body, but the enzyme NADHmethaemoglobin reductase in erythrocytes converts it back to haemoglobin. When large amounts of oxidation take place, this enzyme system becomes saturated and methaemoglobin accumulates. Less oxygen being carried and released to the tissues can lead to a functional anaemia 25, 27 .
Methaemoglobinaemia also increases the risk of haemolysis due to oxidant damage to erythrocytes, either directly or through the formation of free radicals. The normal methaemoglobin fraction in healthy people is 0 to 3%. Well individuals have few symptoms at 15% methaemoglobin, but levels of 20 to 30% cause headache, fatigue, exercise intolerance and dizziness, and can lead to confusion and syncope 28, 29 . Death does not usually occur until the fraction is greater than 50%. Levels of methaemoglobin less than 5% are generally thought to be innocuous 29, 30 . However, in patients who are already compromised by illness such as cardiovascular disease, anaemia, sepsis or other abnormal haemoglobins, a small reduction in oxygen delivery may become important 25, 26, 31 . Our study found that higher peak methaemoglobin levels normally considered non-toxic were associated with an increased risk of mortality that was independent of illness severity 25, 27 . The median iNO concentration used in the study population was 20 ppm, a dose not expected to cause clinically significant levels of methaemoglobin 32 . In our study we did not find an association between the peak methaemoglobin concentrations and the concentration of iNO used, as this was most commonly 20 ppm.
In this study, the Charlson comorbidity score and SOFA score change were all found to be independent predictors of mortality. This emphasises the robustness of our regression models as these scoring systems have been well validated in past research 9, 11, 14 . SAPS II and APACHE II scores were no longer independent mortality predictors when SOFA score change was incorporated into the model. Elevated methaemoglobin levels may be a surrogate marker ofharm. Non-respiratory SOFA scores increased in the 24 hours after iNO commencement even in 'responders'. This creates concern that iNO may have been causing harm by elevating the methaemoglobin fraction of seriously ill patients. Other potential side-effects of iNO include alveolar cell damage due to formation of nitrogen dioxide, decreased platelet aggregation, rebound deterioration in arterial oxygenation and elevation of pulmonary arterial pressure, all of which may contribute to an increased risk of mortality 3 . We did not find a deterioration in renal SOFA scores associated with peak methaemoglobin concentration. 
STUDY STRENGTHS AND LIMITATIONS
The main strength of this study was its large sample size and inclusion of all patients who received iNO during the study period and were able to be assessed for demographic, severity of illness scores and mortality outcomes. Most studies of iNO only have small patient numbers 5 . However, although not all patients had complete data for their methaemoglobin concentrations available, this was accounted for in the analysis methodology. Another strength of our study was the use of a number of standardised disease severity scores in order to better compare patients. By collecting serial SOFA scores, it was possible to quantitatively monitor patient progress after iNO was initiated, rather than relying on charted notes. The logistic regression of mortality was robust, with strong goodness-of-fit and discrimination arguing for validity of the mortality risk factor findings. The Charlson comorbidity score 11 , SOFA 14 change and peak methaemoglobin concentration were all demonstrated to be independent predictors of mortality. Unlike most large studies of iNO, our study was not supported by funding from any iNO manufacturing bodies.
The cohort design of our study limited comparison groups to 'responders' and 'non-responders'. However, it represents an appropriate design to signal that even small increases in methaemoblobin may be a marker of mortality in the critically ill. Despite its retrospective analysis, data collection was complete for those patients where methaemoglobin concentrations were available. However, some confounders of interest such as specific infectious aetiologies could not be extracted from the available dataset and the initiation, dose and weaning of iNO therapy was not uniform despite the presence of unit practice guidelines. Outcome assessment was limited to ICU mortality where data was complete.
CONCLUSION
This audit showed no survival advantage for 'responders' to iNO but confirmed that oxygenation can be improved in some patients with severe respiratory failure. Of concern, peak methaemoglobin levels in patients receiving iNO predicts mortality which has not been demonstrated in any previous studies. The mechanisms for this association need to be explored but in the interim perhaps a lower level of 'safe' methaemoblobinaemia should be considered and iNO concentrations aimed to target a minimal methaemoglobin concentration where oxygenation has been improved.
